|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ezetimibe]] |
| {{Ezetimibe}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for [[atherosclerotic vascular disease]] due to [[hypercholesterolemia]]. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
| |
| | |
| ===Primary Hyperlipidemia===
| |
| | |
| ====Monotherapy====
| |
| | |
| ZETIA®, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) [[hyperlipidemia]].
| |
| | |
| ====Combination Therapy with HMG-CoA Reductase Inhibitors (Statins)====
| |
| | |
| ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) [[hyperlipidemia]].
| |
| | |
| ====Combination Therapy with Fenofibrate====
| |
| | |
| ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed [[hyperlipidemia]].
| |
| | |
| ====Homozygous Familial Hypercholesterolemia (HoFH)====
| |
| | |
| The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
| |
| | |
| ===Homozygous Sitosterolemia===
| |
| | |
| ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
| |
| | |
| ===Limitations of Use===
| |
| | |
| The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
| |
| | |
| ZETIA has not been studied in Fredrickson Type I, III, IV, and V [[dyslipidemia]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZETIA (EZETIMIBE) TABLET [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a | publisher = | date = | accessdate = 11 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Hypolipidemic agents]]
| |
| [[Category:Lactams]]
| |
| [[Category:Merck]]
| |
| [[Category:Schering-Plough]]
| |
| [[Category:Azetidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Phenols]]
| |
| [[Category:Cardiovasuclar Drugs]]
| |
| [[Category:Drugs]]
| |